Indication
Menactra vaccine is given to persons 2 through 55 years of age for active immunization against invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135. Menactra vaccine will not stimulate protection against infection caused by N meningitidis other than serogroups A, C, Y, and W-135.
Safety Information
Side effects to Menactra vaccine include injection site pain, redness, and swelling; headache or fatigue. Other side effects may occur. Vaccination should be avoided by persons with known hypersensitivity (severe allergic reaction) to any ingredient of the vaccine, including latex (which is used in the vial stopper), or by any persons previously diagnosed with Guillain-Barré syndrome. There is a potential for an increased chance of getting Guillain-Barré syndrome following vaccination. Vaccination with Menactra vaccine may not protect all individuals.
For more information about Menactra vaccine, talk to your health-care professional.